Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85884 | 0.91 | LMNA (0.43) | F10POLBEPHX2KMT2AMAPT | |
| SCHEMBL76181 | 0.85 | F10 (0.47) | F10POLBKLKB1CCR1EPHX2 | |
| SCHEMBL75996 | 0.79 | TRPV1 (0.53) | F10POLBKLKB1MAPT | |
| SCHEMBL8470830 | 0.77 | F10 (0.57) | F10POLBKLKB1KMT2ACYP3A4 | |
| SCHEMBL12371425 | 0.77 | F10 (0.57) | F10POLBKLKB1KMT2ACYP3A4 | |
| SCHEMBL77710 | 0.76 | F10 (0.66) | F10POLBKLKB1CYP3A4MAPT | |
| SCHEMBL85147 | 0.76 | F10 (0.66) | F10POLBKLKB1CYP3A4MAPT | |
| SCHEMBL3834358 | 0.75 | F10 (0.62) | F10POLBKLKB1KMT2AMAPT | |
| SCHEMBL3590288 | 0.75 | F10 (0.62) | F10POLBKLKB1CCR1KMT2A | |
| SCHEMBL78036 | 0.75 | CCR2 (0.45) | F10POLBKLKB1CCR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | claimed |
| US-20060183739-A1 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | claimed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20060183739-A1 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
| WO-2006032342-A2 | CARBONYL COMPOUND-CONTAINING DRUG AND THE USE THEREOF | MERCK PATENT GMBH (DE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | F10 5/4885POLB 2957/4885KLKB1 723/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | F10 22/4885POLB 3094/4885KLKB1 2357/4885 |
| US-20060183739-A1 | Carbonyl compounds | F2, F11, PDHX | F10 5/4885POLB 2957/4885KLKB1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.